Роль алендроновой кислоты (осталон) в лечении перименопаузального остеопороза

Аннотация

Purpose of the study: study and evaluation of biphosphonates in the treatment and prevention of perimenopau-sal osteoporosis. 60 perimenopausal patients were examined. In both groups, age are ranged from 45 to 55. The first group consisted of women who were offered alendronic acid dose of 70 mg per week for 6 months. The second group includes patients who, for economic reasons, did not take the above drug. The examined women determined the level of calcium and alkaline phosphates in the blood. The determination of bone mineral density was carried out using the ultrasonic densitometry method. From the above situation it is obvious that treatment with a group of biphosphonates, in particular alendronic acid 70 mg per week, significantly increases bone mineral density, which in turn prevents atraumatic fractures in women in the perimenopausal period.